Alexza Pharmaceuticals Inc. Watch

from 8-K 6 pages Amended and Restated Promissory Note

from 10-Q 24 pages Registration Rights Agreement

from 10-Q 12 pages Alexza Pharmaceuticals, Inc. Stock Issuance Agreement

from 10-Q 8 pages Amended and Restated Promissory Note and Agreement to Lend

from 10-Q 37 pages Amendment No. 2 to License and Supply Agreement

from 8-K 117 pages Amended and Restated Promissory Note

from 8-K/A 4 pages Highly Confidential Alexza Pharmaceuticals Inc. 2091 Stierlin Court Mountain View, Ca 94043 United States Attention: Ms. Tatjana Naranda Director Business Development & Global Alliance Management Ladies and Gentleman: 1. Upfront Payment 1.04 Usd Per Share on a Fully-Diluted Basis and Cash Payments to Warrant Holders With Out-Of-The-Money Warrants Based on Their Black-Scholes Value. This Assumes 100% Fully-Diluted Shares. 2. Contingent Value Rights (“Cvrs”) Cvrs Based on the Achievement of Pre-Specified Events Outlined Below and Are Structured to Preserve a 251(h) Tender Offer Structure: R.M.B. 06.10.98, Tomo 31.026, Folio 39, Hoja N° B-184105, Inscription 1e, N.I.F. A-61738993

from 8-K/A 6 pages Promissory Note

from 8-K/A 6 pages Promissory Note

from 8-K 12 pages Alexza Pharmaceuticals, Inc. Stock Issuance Agreement

from 8-K 5 pages Promissory Note

from 10-Q 11 pages Amended and Restated Convertible Promissory Note and Agreement to Lend

from 10-Q 21 pages Amendment No. 1 to License and Supply Agreement

from 10-Q 9 pages Fourth Amendment to Collaboration, License and Supply Agreement

from 8-K 14 pages Confidential Release Agreement

from 10-K 13 pages Alexza Pharmaceuticals, Inc. Stock Purchase Agreement

from 10-K 2 pages Third Amendment to the Collaboration, License and Supply Agreement

from 10-K 3 pages Second Amendment to Collaboration, License and Supply Agreement

from 10-K 6 pages Amendment No. 3 to Manufacturing and Supply Agreement

from 8-K 4 pages Alexza Pharmaceuticals, Inc. 2015 Cash Bonus Plan